Literature DB >> 11032931

Adenosine receptor antagonism causes inhibition of angiogenic activity of human ovarian cancer cells.

E Barcz1, E Sommer, P Janik, L Marianowski, E Skopinska-Rózewska.   

Abstract

Angiogenesis, new blood vessels development, is an important process involved in ovarian cancer growth and metastasis. Adenosine is a known mediator of angiogenesis in hypoxic tissues. Theobromine, adenosine receptor antagonist, exerts antiangiogenic properties in many types of tumors in Balb/c mice cutaneous angiogenesis assay. The aim of the present study was to evaluate the mechanism of its action. We showed that theobromine inhibits angiogenic activity of ovarian cancer cells as well as CD45 positive lymphocytes isolated from peritoneal ascitic fluid of ovarian cancer patients. Using synthetic adenosine receptor antagonists: 8-phenyl-theophylline and 8-cyclopentyl-1,3 dipropylxantine we established that antiangiogenic properties of theobromine are dependent on its interaction with A2 adenosine receptor. Our observations were confirmed in full suspensions of ascitic cells as well as in isolated cancer cells and CD45 lymphocytes. We postulate that A2 receptor antagonism may diminish angiogenesis induced by hypoxia in different cancer tissues and may find a place in future cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11032931     DOI: 10.3892/or.7.6.1285

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  9 in total

1.  Diminution in adenine nucleotide hydrolysis by platelets and serum from rats submitted to Walker 256 tumour.

Authors:  Andréia Buffon; Vanessa B Ribeiro; Alessandra S Schanoski; João J F Sarkis
Journal:  Mol Cell Biochem       Date:  2006-01       Impact factor: 3.396

2.  CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver.

Authors:  S Cohen; S M Stemmer; G Zozulya; A Ochaion; R Patoka; F Barer; S Bar-Yehuda; L Rath-Wolfson; K A Jacobson; P Fishman
Journal:  J Cell Physiol       Date:  2011-09       Impact factor: 6.384

Review 3.  Purinergic signalling and cancer.

Authors:  Geoffrey Burnstock; Francesco Di Virgilio
Journal:  Purinergic Signal       Date:  2013-12       Impact factor: 3.765

4.  Salinivibrio costicola GL6, a Novel Isolated Strain for Biotransformation of Caffeine to Theobromine Under Hypersaline Conditions.

Authors:  Morahem Ashengroph
Journal:  Curr Microbiol       Date:  2016-10-19       Impact factor: 2.188

5.  Adenosine down-regulates the surface expression of dipeptidyl peptidase IV on HT-29 human colorectal carcinoma cells: implications for cancer cell behavior.

Authors:  Ernest Y Tan; Michelle Mujoomdar; Jonathan Blay
Journal:  Am J Pathol       Date:  2004-07       Impact factor: 4.307

Review 6.  Immunity, inflammation and cancer: a leading role for adenosine.

Authors:  Luca Antonioli; Corrado Blandizzi; Pál Pacher; György Haskó
Journal:  Nat Rev Cancer       Date:  2013-11-14       Impact factor: 60.716

Review 7.  Targeting purine metabolism in ovarian cancer.

Authors:  Jingchun Liu; Shasha Hong; Jiang Yang; Xiaoyi Zhang; Ying Wang; Haoyu Wang; Jiaxin Peng; Li Hong
Journal:  J Ovarian Res       Date:  2022-08-13       Impact factor: 5.506

8.  The effect of pentoxifylline on L-1 sarcoma tumor growth and angiogenesis in Balb/c mice.

Authors:  Barbara Joanna Bałan; Urszula Demkow; Piotr Skopiński; Małgorzata Bychawska; Ewa Skopińska-Różewska; Sławomir Lewicki; Robert Zdanowski
Journal:  Cent Eur J Immunol       Date:  2017-08-08       Impact factor: 2.085

Review 9.  Xanthine scaffold: scope and potential in drug development.

Authors:  Nivedita Singh; Ashwinee Kumar Shreshtha; M S Thakur; Sanjukta Patra
Journal:  Heliyon       Date:  2018-10-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.